Thanks Pete.
Upon reading the article it seems to me that we could equally qualify for Orphan Drug Designation as well as Breakthrough Therapy.
I'd like to know if there is a reason not to pursue both avenues.
If we achieve FDA approval for Breakthrough Therapy then surely an interested party would be eager to advance a proposal to PAA
Ann: PharmAust to present at Emerging ASX Gems Conference, page-47
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.24M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16250 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 356146 | 8 |
View Market Depth
| Last trade - 07.33am 01/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable